CCL3 (MIP-1α) levels are elevated during acute coronary syndromes and show strong prognostic power for future ischemic events

Journal of Molecular and Cellular Cardiology

Volumn 45, Issue 3, 2008, Pages 446-452

  de Jager, Saskia C A ^a   Kraaijeveld, Adriaan O ^a,b   Grauss, Robert W ^b   de Jager, Wilco ^c   Liem, Su San ^b   van der Hoeven, Bas L ^b   Prakken, Berent J ^c   Putter, Hein ^b   van Berkel, Theo J C ^a   Atsma, Douwe E ^b   Schalij, Martin J ^b   Jukema, J Wouter ^b   Biessen, Erik A L ^a,d  

^a LEIDEN UNIVERSITY   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^d MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

Acute coronary syndromes; Biomarker; Cardiac ischemia; Chemokines

Indexed keywords

BIOLOGICAL MARKER; CHEMOKINE; CHEMOKINE RECEPTOR CCR5; CXCL9 CHEMOKINE; EOTAXIN; GAMMA INTERFERON INDUCIBLE PROTEIN 10; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 2; INTERLEUKIN 6; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1; RANTES; THYMUS AND ACTIVATION REGULATED CHEMOKINE; TUMOR NECROSIS FACTOR ALPHA;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CELL COUNT; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; FEMALE; HEART MUSCLE ISCHEMIA; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; REPERFUSION INJURY; T LYMPHOCYTE; UNSTABLE ANGINA PECTORIS;

ACUTE CORONARY SYNDROME; AGED; ANGINA, UNSTABLE; ANIMALS; CHEMOKINE CCL3; COHORT STUDIES; DISEASE MODELS, ANIMAL; FEMALE; FORECASTING; HUMANS; MALE; MICE; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIAL ISCHEMIA; PILOT PROJECTS; PROGNOSIS; PROSPECTIVE STUDIES;

ANGINA; MUS;

EID: 50449095582     PISSN: 00222828     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2008.06.003     Document Type: Article

References (41)

1. Baltus T., von Hundelshausen P., Mause S.F., Buhre W., Rossaint R., and Weber C. Differential and additive effects of platelet-derived chemokines on monocyte arrest on inflamed endothelium under flow conditions. J. Leukoc. Biol. 78 2 (2005) 435-441
2. Simeoni E., Winkelmann B.R., Hoffmann M.M., Fleury S., Ruiz J., Kappenberger L., et al. Association of RANTES G-403A gene polymorphism with increased risk of coronary arteriosclerosis. Eur. Heart. J. 25 16 (2004) 1438-1446
3. Boger C.A., Fischereder M., Deinzer M., Aslanidis C., Schmitz G., Stubanus M., et al. RANTES gene polymorphisms predict all-cause and cardiac mortality in type 2 diabetes mellitus hemodialysis patients. Atherosclerosis 183 1 (2005) 121-129
4. Tarzami S.T., Miao W., Mani K., Lopez L., Factor S.M., Berman J.W., et al. Opposing effects mediated by the chemokine receptor CXCR2 on myocardial ischemia-reperfusion injury: recruitment of potentially damaging neutrophils and direct myocardial protection. Circulation 108 19 (2003) 2387-2392
5. Somasundaram P., Ren G., Nagar H., Kraemer D., Mendoza L., Michael L.H., et al. Mast cell tryptase may modulate endothelial cell phenotype in healing myocardial infarcts. J. Pathol. 205 1 (2005) 102-111
6. Schomig K., Busch G., Steppich B., Sepp D., Kaufmann J., Stein A., et al. Interleukin-8 is associated with circulating CD133+ progenitor cells in acute myocardial infarction. Eur. Heart. J. 27 9 (2006) 1032-1037
7. Vandervelde S., van Luyn M.J., Rozenbaum M.H., Petersen A.H., Tio R.A., and Harmsen M.C. Stem cell-related cardiac gene expression early after murine myocardial infarction. Cardiovasc. Res. 73 4 (2007) 783-793
8. Akasaka Y., Morimoto N., Ishikawa Y., Fujita K., Ito K., Kimura-Matsumoto M., et al. Myocardial apoptosis associated with the expression of proinflammatory cytokines during the course of myocardial infarction. Mod. Pathol. 19 4 (2006) 588-598
9. Murakami Y., Kurosaki K., Matsui K., Shimada K., and Ikeda U. Serum MCP-1 and VEGF levels are not affected by inhibition of the renin-angiotensin system in patients with acute myocardial infarction. Cardiovasc. Drugs Ther. 17 3 (2003) 249-255
10. Frangogiannis N.G. The role of the chemokines in myocardial ischemia and reperfusion. Curr. Vasc. Pharmacol. 2 2 (2004) 163-174
11. Liem S.S., van der Hoeven B.L., Oemrawsingh P.V., Bax J.J., van der Bom J.G., Bosch J., et al. MISSION!: optimization of acute and chronic care for patients with acute myocardial infarction. Am. Heart. J. 153 1 (2007) 14.e1-14.e11
12. Verheggen P.W., de Maat M.P., Cats V.M., Haverkate F., Zwinderman A.H., Kluft C., et al. Inflammatory status as a main determinant of outcome in patients with unstable angina, independent of coagulation activation and endothelial cell function. Eur. Heart. J. 20 8 (1999) 567-574
13. de Jager W. Simultaneous detection of 15 human cytokines in a single sample of stimulated peripheral blood mononuclear cells. clinical and diagnostic laboratory immunology 10 1 (2003) 133-139
14. de Jager W., Prakken B.J., Bijlsma J.W., Kuis W., and Rijkers G.T. Improved multiplex immunoassay performance in human plasma and synovial fluid following removal of interfering heterophilic antibodies. J. Immunol. Methods 300 1-2 (2005) 124-135
15. Herder C., Baumert J., Thorand B., Martin S., Lowel H., Kolb H., et al. Chemokines and incident coronary heart disease: results from the MONICA/KORA Augsburg case-cohort study, 1984-2002. Arterioscler Thromb Vasc. Biol. 26 9 (2006) 2147-2152
16. Garau A., Bertini R., Colotta F., Casilli F., Bigini P., Cagnotto A., et al. Neuroprotection with the CXCL8 inhibitor repertaxin in transient brain ischemia. Cytokine 30 3 (2005) 125-131
17. Villa P., Triulzi S., Cavalieri B., Di Bitondo R., Bertini R., Barbera S., et al. The interleukin-8 (IL-8/CXCL8) receptor inhibitor reparixin improves neurological deficits and reduces long-term inflammation in permanent and transient cerebral ischemia in rats. Mol. Med. 13 3-4 (2007) 125-133
18. Waeckel L., Mallat Z., Potteaux S., Combadiere C., Clergue M., Duriez M., et al. Impairment in postischemic neovascularization in mice lacking the CXC chemokine receptor 3. Circ. Res. 96 5 (2005) 576-582
19. Souza D.G., Bertini R., Vieira A.T., Cunha F.Q., Poole S., Allegretti M., et al. Repertaxin, a novel inhibitor of rat CXCR2 function, inhibits inflammatory responses that follow intestinal ischaemia and reperfusion injury. Br. J. Pharmacol. 143 1 (2004) 132-142
20. Kraaijeveld A.O., de Jager S.C., de Jager W.J., Prakken B.J., McColl S.R., Haspels I., et al. CC chemokine ligand-5 (CCL5/RANTES) and CC chemokine ligand-18 (CCL18/PARC) are specific markers of refractory unstable angina pectoris and are transiently raised during severe ischemic symptoms. Circulation 116 17 (2007) 1931-1941
21. de Maat M.P., Haverkate F., and Kluft C. Relationship between CRP and clinical course of unstable angina depends on assay method. Vascul. Pharmacol. 39 3 (2002) 113-115
22. Zhou R.H., Shi Q., Gao H.Q., and Shen B.J. Changes in serum interleukin-8 and interleukin-12 levels in patients with ischemic heart disease in a Chinese population. J. Atheroscler Thromb 8 1 (2001) 30-32
23. Hashmi S., and Zeng Q.T. Role of interleukin-17 and interleukin-17-induced cytokines interleukin-6 and interleukin-8 in unstable coronary artery disease. Coron Artery Dis. 17 8 (2006) 699-706
24. Parissis J.T., Adamopoulos S., Venetsanou K.F., Mentzikof D.G., Karas S.M., and Kremastinos D.T. Serum profiles of C-C chemokines in acute myocardial infarction: possible implication in postinfarction left ventricular remodeling. J. Interferon Cytokine Res. 22 2 (2002) 223-229
25. Nomura S., Uehata S., Saito S., Osumi K., Ozeki Y., and Kimura Y. Enzyme immunoassay detection of platelet-derived microparticles and RANTES in acute coronary syndrome. Thromb Haemost 89 3 (2003) 506-512
26. LaFramboise W.A., Bombach K.L., Dhir R.J., Muha N., Cullen R.F., Pogozelski A.R., et al. Molecular dynamics of the compensatory response to myocardial infarct. J. Mol. Cell. Cardiol. 38 1 (2005) 103-117
27. Shu J., Ren N., Du J.B., Zhang M., Cong H.L., and Huang T.G. Increased levels of interleukin-6 and matrix metalloproteinase-9 are of cardiac origin in acute coronary syndrome. Scand. Cardiovasc. J. 41 3 (2007) 149-154
28. Miyao Y., Yasue H., Ogawa H., Misumi I., Masuda T., Sakamoto T., et al. Elevated plasma interleukin-6 levels in patients with acute myocardial infarction. Am. Heart. J. 126 6 (1993) 1299-1304
29. Mizia-Stec K., Gasior Z., Zahorska-Markiewicz B., Janowska J., Szulc A., Jastrzebska-Maj E., et al. Serum tumour necrosis factor-alpha, interleukin-2 and interleukin-10 activation in stable angina and acute coronary syndromes. Coron Artery Dis. 14 6 (2003) 431-438
30. Wang Y.N., Che S.M., and Ma A.Q. Clinical significance of serum cytokines IL-1beta, sIL-2R, IL-6, TNF-alpha, and IFN-v in acute coronary syndrome. Chin. Med. Sci. J. 19 2 (2004) 120-124
31. de Lemos J.A., Hennekens C.H., and Ridker P.M. Plasma concentration of soluble vascular cell adhesion molecule-1 and subsequent cardiovascular risk. J. Am. Coll. Cardiol. 36 2 (2000) 423-426
32. Mause S.F., von Hundelshausen P., Zernecke A., Koenen R.R., and Weber C. Platelet microparticles: a transcellular delivery system for RANTES promoting monocyte recruitment on endothelium. Arterioscler Thromb Vasc. Biol. 25 7 (2005) 1512-1518
33. Matsumori A., Furukawa Y., Hashimoto T., Yoshida A., Ono K., Shioi T., et al. Plasma levels of the monocyte chemotactic and activating factor/monocyte chemoattractant protein-1 are elevated in patients with acute myocardial infarction. J. Mol. Cell. Cardiol. 29 1 (1997) 419-423
34. Damas J.K., Boullier A., Waehre T., Smith C., Sandberg W.J., Green S., et al. Expression of fractalkine (CX3CL1) and its receptor, CX3CR1, is elevated in coronary artery disease and is reduced during statin therapy. Arterioscler Thromb Vasc. Biol. 25 12 (2005) 2567-2572
35. Garlichs C.D., Eskafi S., Raaz D., Schmidt A., Ludwig J., Herrmann M., et al. Patients with acute coronary syndromes express enhanced CD40 ligand/CD154 on platelets. Heart 86 6 (2001) 649-655
36. Andre P., Nannizzi-Alaimo L., Prasad S.K., and Phillips D.R. Platelet-derived CD40L: the switch-hitting player of cardiovascular disease. Circulation 106 8 (2002) 896-899
37. Koh K.K., Son J.W., Ahn J.Y., Choi Y.M., Jin D.K., Park G.S., et al. Non-lipid effects of statin on hypercholesterolemic patients established to have coronary artery disease who remained hypercholesterolemic while eating a step-II diet. Coron Artery Dis. 12 4 (2001) 305-311
38. Rezaie-Majd A., Maca T., Bucek R.A., Valent P., Muller M.R., Husslein P., et al. Simvastatin reduces expression of cytokines interleukin-6, interleukin-8, and monocyte chemoattractant protein-1 in circulating monocytes from hypercholesterolemic patients. Arterioscler Thromb Vasc. Biol. 22 7 (2002) 1194-1199
39. Rallidis L.S., Hamodraka E.S., Fountoulaki K., Moustogiannis G., Zolindaki M.G., and Kremastinos D.T. Simvastatin exerts its anti-inflammatory effect in hypercholesterolaemic patients by decreasing the serum levels of monocyte chemoattractant protein-1. Int. J. Cardiol. 124 2 (2008) 271-272
40. Takata M., Urakaze M., Temaru R., Yamazaki K., Nakamura N., Nobata Y., et al. Pravastatin suppresses the interleukin-8 production induced by thrombin in human aortic endothelial cells cultured with high glucose by inhibiting the p44/42 mitogen activated protein kinase. Br. J. Pharmacol. 134 4 (2001) 753-762
41. Kibayashi E., Urakaze M., Kobashi C., Kishida M., Takata M., Sato A., et al. Inhibitory effect of pitavastatin (NK-104) on the C-reactive-protein-induced interleukin-8 production in human aortic endothelial cells. Clin. Sci. (Lond) 108 6 (2005) 515-521